Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaisa Health Group Holdings's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.37.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.46.
During the past 3 years, the average EBIT per Share Growth Rate was 6.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -7.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Kaisa Health Group Holdings's EBIT per Share or its related term are showing as below:
HKSE:00876'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -142.2 Med: -7.6 Max: 30.4
Current: 6.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Kaisa Health Group Holdings was 30.40% per year. The lowest was -142.20% per year. And the median was -7.60% per year.
HKSE:00876's 3-Year EBIT Growth Rate is ranked worse than 53.16% of 681
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs HKSE:00876: 6.80
Kaisa Health Group Holdings (HKSE:00876) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Kaisa Health Group Holdings EBIT per Share Related Terms
Kaisa Health Group Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaisa Health Group Holdings (HKSE:00876) has a EBIT per Share of HK$-0.46 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Kaisa Health Group Holdings and its competitors. According to the industry distribution chart, Kaisa Health Group Holdings ranks #362 out of 681 companies in the Medical Devices & Instruments industry, placing it in the top 53.2%.
Is Kaisa Health Group Holdings' EBIT per Share too high?
Kaisa Health Group Holdings' current EBIT per Share is HK$-0.46. Based on the distribution chart, Kaisa Health Group Holdings ranks #362 out of 681 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kaisa Health Group Holdings has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kaisa Health Group Holdings' EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Kaisa Health Group Holdings ranks #362 out of 681 companies for EBIT per Share. This places Kaisa Health Group Holdings in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Kaisa Health Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaisa Health Group Holdings's current EBIT per Share is HK$-0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaisa Health Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kaisa Health Group Holdings (HKSE:00876) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.95, compared to a current price of HK$2.21 — trading 132.6% above its estimated fair value. The current EBIT per Share is HK$-0.46. Kaisa Health Group Holdings' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Kaisa Health Group Holdings (HKSE:00876), the current EBIT per Share is HK$-0.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaisa Health Group Holdings (HKSE:00876) Overvalued in 2026?
Based on GuruFocus' analysis, Kaisa Health Group Holdings stock appears to be overvalued.
The current stock price of HK$2.21 is trading 132.6% above its estimated GF Value™ of HK$0.95.
GuruFocus considers Kaisa Health Group Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00876:
EBIT per Share: HK$-0.46
GF Value™: HK$0.95 vs. price of HK$2.21 (132.6% above fair value)
No single metric tells the full story. See the HKSE:00876 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaisa Health Group Holdings Ltd, through its subsidiaries are mainly engaged in the manufacturing and sale of dental prosthetics and implant instruments, and the provision of sports rehabilitation services. The Group operates in two reportable segments: Dental Business, which consists of manufacturing and trading in dental products; and the Health Care Business, which provides services for sport rehabilitation, including postoperative rehabilitation, sports injury rehabilitation, chronic pain, scoliosis, deformity correction, other rehabilitation services, and health leisure business. The majority of its revenue is generated from the Dental business segment. Geographically, the Group generates maximum revenue from the People's Republic of China, and the rest from other countries.
37GF Score
Get the complete analysis for HKSE:00876
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00876 has been successfully added to your 
